Who are Morphine and Midazolam's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/morphine-and-midazolam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Morphine and Midazolam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Morphine and Midazolam (Morphine and Midazolam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic and benzodiazepine sedative combination. Area: Pain management, Palliative care, Acute care sedation.

marketed Opioid analgesic and benzodiazepine sedative combination Mu opioid receptor; GABA-A receptor Pain management, Palliative care, Acute care sedation Small molecule Live · refreshed every 30 min

Target snapshot

Morphine and Midazolam (Morphine and Midazolam) — Ain Shams University. Morphine is an opioid agonist that binds mu opioid receptors to reduce pain perception, while midazolam is a benzodiazepine that enhances GABA inhibitory signaling to produce sedation and anxiolysis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Morphine and Midazolam TARGET	Morphine and Midazolam	Ain Shams University	marketed	Opioid analgesic and benzodiazepine sedative combination	Mu opioid receptor; GABA-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic and benzodiazepine sedative combination class)

Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Morphine and Midazolam — Competitive Intelligence Brief. https://druglandscape.com/ci/morphine-and-midazolam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing